Furthermore, oxymatrine decreased FAS enzymatic activity and increased CPT1A enzymatic activity in mice with NAFLD induced by high glucose, inhibiting hepatic lipid synthesis [97]. Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.